Switch to: References

Add citations

You must login to add citations.
  1. Reconceptualising risk–benefit analyses: the case of HIV cure research.Robert Steel - 2020 - Journal of Medical Ethics 46 (3):212-219.
    Modern antiretroviral therapies are capable of suppressing HIV in the bloodstream to undetectable levels. Nonetheless, people living with HIV must maintain lifelong adherence to ART to avoid the re-emergence of the infection. So despite the existence and efficacy of ART, there is still substantial interest in development of a cure. But HIV cure trials can be risky, their success is as of yet unlikely, and the medical gain of being cured is limited against a baseline of ART access. The medical (...)
    Download  
     
    Export citation  
     
    Bookmark   6 citations  
  • Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.Stuart Rennie, Maartje Dijkstra, Karine Dubé, Joseph D. Tucker & Adam Gilbertson - 2021 - BMC Medical Ethics 22 (1):1-12.
    HIV remission clinical researchers are increasingly seeking study participants who are diagnosed and treated during acute HIV infection—the brief period between infection and the point when the body creates detectable HIV antibodies. This earliest stage of infection is often marked by flu-like illness and may be an especially tumultuous period of confusion, guilt, anger, and uncertainty. Such experiences may present added ethical challenges for HIV research recruitment, participation, and retention. The purpose of this paper is to identify potential ethical challenges (...)
    Download  
     
    Export citation  
     
    Bookmark